FDA approves initiation of Phase I clinical trial for cervical cancer and oropharyngeal cancer
Tessa Therapeutics’ research partner, Baylor College of Medicine (Baylor), received US Food and Drug Administration (FDA) approval in June 2015 to initiate Phase I clinical trials involving adoptive HPV-specific T Cell therapy to treat HPV-associated cervical cancer and oropharyngeal cancer. Approximately 700,000 new cases of cervical cancer and oropharyngeal cancer are diagnosed every year, with up to 70- 80% of these cases being positive for HPV.
Partnership with Baylor College of Medicine to develop HPV-specific T Cell therapy for all HPV-related cancers
Tessa Therapeutics and Baylor College of Medicine (Baylor) entered into a partnership to develop Baylor’s HPV-specific immunotherapy. Under the agreement signed in Feb 2015, Tessa Therapeutics has the exclusive right to license Baylor’s HPV-specific T Cell therapy for all HPV-related cancers including cervical and oropharyngeal cancers.
Tessa Therapeutics’ head and neck cancer therapy granted Fast Track designation
The US Food and Drug Administration (FDA) granted Fast Track designation to Tessa Therapeutics’ EBV-specific adoptive T Cell therapy for head and neck cancers in September 2015. The designation enables Tessa Therapeutics to have more frequent interactions with the agency, including a potential rolling review of Tessa Therapeutics’ application, and the ability to expedite the development of Tessa Therapeutics’ EBV-specific adoptive T Cell therapy.
FDA approves initiation of Phase III clinical trial for nasopharyngeal cancer
Tessa Therapeutics received US Food and Drug Administration (FDA) approval in March 2015 to initiate a Phase III clinical trial involving adoptive EBV-specific T Cell therapy to treat nasopharyngeal cancer. This is the world’s first and largest Phase III T Cell therapy cancer trial. Tessa Therapeutics has an exclusive license to EBV-specific T Cell technology from the National Cancer Centre Singapore (NCCS).